芒果视频下载

網(wang)站分類
登錄 |    
夏術階
0 票數:0 #醫生#
夏術階,醫學博士,博士研究生導師,上海交通大學附屬第一人民醫院副院長、泌尿外科臨床醫學中心主任,上海交通大學泌尿外科研究所所長。他是泌尿外科最高榮譽獎“吳階平醫學獎”獲得者,獲得2019年中國文明網“中國好醫生”10月月度人物榮譽。他創建的“銩激光剝橘式前列腺切除術”治療良性前列腺增生癥得到國際F1000點評機構的高度評價,獲得省部級科學技術進步二等獎2項,三等獎1項。
  • 中文名: 夏(xia)術(shu)階(jie)
  • 性別:
  • 國籍: 中(zhong)國(guo)
  • 畢業院校: 山東(dong)醫科(ke)大學
  • 職業職位: 教(jiao)師,醫生(sheng),編輯(ji)
  • 代表作品: 主編《微創泌尿(niao)外科手術學》前列腺癌》等6部專著(zhu)
  • 主要成就: 獲得教育部211學科(ke)建設基金(jin)資助,獲得國家專利12項
本百科詞條由網站注冊用戶"歲月靜好"編輯上傳提供,詞條屬于開放詞條,當前頁面所展示的百科詞條介紹涉及宣傳內容屬于注冊用戶個人編輯行為。與夏術階的所屬企業/主題/所有人主體無關,詞條主體可以提供資料認證申請管理本詞條權限免費更新資料,也可以因內容與實際情況不符快速在線向網站提出反饋修改! 反饋
詳細介紹 PROFILE +

人物簡介

《中(zhong)華(hua)醫(yi)學(xue)(xue)(xue)(xue)雜志(zhi)(zhi)》副(fu)總編(bian)輯,上(shang)(shang)海(hai)(hai)(hai)(hai)第一人(ren)民(min)(min)醫(yi)院(yuan)(yuan)副(fu)院(yuan)(yuan)長、上(shang)(shang)海(hai)(hai)(hai)(hai)交通大學(xue)(xue)(xue)(xue)泌尿外(wai)(wai)科(ke)(ke)研究所(suo)(suo)所(suo)(suo)長、上(shang)(shang)海(hai)(hai)(hai)(hai)交通大學(xue)(xue)(xue)(xue)附屬第一人(ren)民(min)(min)醫(yi)院(yuan)(yuan)泌尿外(wai)(wai)科(ke)(ke)主(zhu)任、教授、博士研究生導師。上(shang)(shang)海(hai)(hai)(hai)(hai)激光(guang)學(xue)(xue)(xue)(xue)會(hui)(hui)(hui)(hui)副(fu)理事(shi)長,中(zhong)華(hua)醫(yi)學(xue)(xue)(xue)(xue)會(hui)(hui)(hui)(hui)男科(ke)(ke)學(xue)(xue)(xue)(xue)會(hui)(hui)(hui)(hui)上(shang)(shang)海(hai)(hai)(hai)(hai)分(fen)會(hui)(hui)(hui)(hui)侯任主(zhu)任委(wei)(wei)員(yuan),中(zhong)華(hua)醫(yi)學(xue)(xue)(xue)(xue)會(hui)(hui)(hui)(hui)泌尿外(wai)(wai)科(ke)(ke)學(xue)(xue)(xue)(xue)會(hui)(hui)(hui)(hui)常委(wei)(wei)、中(zhong)國(guo)光(guang)學(xue)(xue)(xue)(xue)學(xue)(xue)(xue)(xue)會(hui)(hui)(hui)(hui)生物醫(yi)學(xue)(xue)(xue)(xue)光(guang)子學(xue)(xue)(xue)(xue)專(zhuan)(zhuan)業委(wei)(wei)員(yuan)會(hui)(hui)(hui)(hui)副(fu)主(zhu)任委(wei)(wei)員(yuan),國(guo)際(ji)泌尿外(wai)(wai)科(ke)(ke)學(xue)(xue)(xue)(xue)會(hui)(hui)(hui)(hui)會(hui)(hui)(hui)(hui)員(yuan),南京(jing)醫(yi)科(ke)(ke)大學(xue)(xue)(xue)(xue)外(wai)(wai)科(ke)(ke)學(xue)(xue)(xue)(xue)教授。英文版Aian Journal of Andrology、Current Urology、CMJ編(bian)委(wei)(wei);參加(jia)國(guo)內(nei)外(wai)(wai)22家雜志(zhi)(zhi)編(bian)審的工(gong)作。國(guo)家衛(wei)生部(bu)內(nei)鏡專(zhuan)(zhuan)業技術考評(ping)委(wei)(wei)員(yuan)會(hui)(hui)(hui)(hui)專(zhuan)(zhuan)科(ke)(ke)內(nei)鏡專(zhuan)(zhuan)家委(wei)(wei)員(yuan)會(hui)(hui)(hui)(hui)主(zhu)席,國(guo)家衛(wei)生部(bu)內(nei)鏡專(zhuan)(zhuan)業技術考評(ping)委(wei)(wei)員(yuan)會(hui)(hui)(hui)(hui)專(zhuan)(zhuan)家,國(guo)家自(zi)然基金終審專(zhuan)(zhuan)家組(zu)專(zhuan)(zhuan)家,上(shang)(shang)海(hai)(hai)(hai)(hai)市(shi)醫(yi)學(xue)(xue)(xue)(xue)領軍人(ren)才、上(shang)(shang)海(hai)(hai)(hai)(hai)市(shi)領軍人(ren)才。

主要作品

(1)提出(chu)(chu)了(le)輸(shu)精(jing)管對前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)增(zeng)生(sheng)(sheng)的(de)(de)(de)抑制(zhi)作用(yong)。(2)建立(li)了(le)經(jing)直腸(chang)超聲(sheng)前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)體(ti)積(ji)定量學(xue)研究的(de)(de)(de)方(fang)法(fa),并(bing)(bing)校正了(le)國際(ji)上前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)超聲(sheng)定量學(xue)研究方(fang)法(fa)的(de)(de)(de)誤(wu)差。(3)提出(chu)(chu)并(bing)(bing)論(lun)證了(le)前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)組織中雄(xiong)激素受(shou)體(ti)亞型的(de)(de)(de)新概念。提出(chu)(chu)了(le)前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)組織中雄(xiong)激素受(shou)體(ti)亞型的(de)(de)(de)分布(bu)特征(zheng)和(he)種(zhong)屬特異性(xing)。克(ke)隆出(chu)(chu)了(le)雄(xiong)激素受(shou)體(ti)亞型基因。為(wei)研究阻斷(duan)雄(xiong)激素受(shou)體(ti)亞型的(de)(de)(de)藥物奠定了(le)基礎(chu)。奠定了(le)前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)移(yi)行(xing)帶與周圍帶的(de)(de)(de)分子調控理論(lun)。(4)提出(chu)(chu)了(le)前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)階(jie)段性(xing)增(zeng)長的(de)(de)(de)理論(lun),并(bing)(bing)將前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)的(de)(de)(de)增(zeng)長分為(wei)四個不同時相。即青(qing)春期(qi)(qi)前(qian)(qian)(qian)的(de)(de)(de)緩(huan)(huan)慢增(zeng)長期(qi)(qi);10~30歲的(de)(de)(de)快(kuai)速增(zeng)長期(qi)(qi);30~50歲的(de)(de)(de)再緩(huan)(huan)慢增(zeng)長期(qi)(qi);50~90歲的(de)(de)(de)加速增(zeng)長期(qi)(qi)。提出(chu)(chu)了(le)前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)增(zeng)長與雄(xiong)激素的(de)(de)(de)相互關(guan)系(xi)。(5)發明2微米(銩(diu))激光剝橘式前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)切(qie)除術治療良性(xing)前(qian)(qian)(qian)列(lie)(lie)腺(xian)(xian)(xian)增(zeng)生(sheng)(sheng)癥的(de)(de)(de)手術方(fang)法(fa),EU(IF:8.843),并(bing)(bing)得到(dao)國際(ji)F1000高度評價。

Prof Shu-Jie Xia is a doctorial supervisor and the Vice President of First People's Hospital Affiliated to ShanghaiJiaoTongUniversity, President of Institute of Urology of ShanghaiJiaoTongUniversity, Director of the Department of Urology, First People's Hospital Affiliated to ShanghaiJiaoTongUniversity. He won the Chinese Leadership Award in Endoscopy and International Leadership Award in Endoscopy. In 2010 he was granted the title of Young and Middle-aged Experts with Outstanding Contribution by National Ministry of Health. He was awarded Wu Jie-Ping Medical Prize, the highest honor in Urology in China. He has enjoyed the Special Government Allowance. Prof Xia has obtained 12 national patents, and published 249 papers in international and domestic journals, including more than 50 SCI papers. He is the Editor-in-Chief of six books such as Minimally Invasive Urologic Surgery,Prostate Cancer, etc. His research interests are clinical surgery and basic research on prostate, urogenital tumor, and minimally invasive surgery.

獲獎記錄

先(xian)(xian)后主(zhu)持3項(xiang)(xiang)國(guo)(guo)家(jia)(jia)(jia)(jia)自(zi)然科(ke)(ke)(ke)(ke)學(xue)(xue)基(ji)(ji)(ji)金(jin)課題(ti),獲得(de)(de)教(jiao)育部(bu)211學(xue)(xue)科(ke)(ke)(ke)(ke)建設基(ji)(ji)(ji)金(jin)資(zi)(zi)助。獲得(de)(de)上(shang)(shang)海市(shi)(shi)(shi)優秀學(xue)(xue)科(ke)(ke)(ke)(ke)帶(dai)頭人計劃資(zi)(zi)助,主(zhu)持上(shang)(shang)海市(shi)(shi)(shi)重(zhong)大點研基(ji)(ji)(ji)金(jin)5項(xiang)(xiang)、國(guo)(guo)家(jia)(jia)(jia)(jia)衛(wei)生部(bu)及(ji)吳階平基(ji)(ji)(ji)金(jin)會以及(ji)省(sheng)部(bu)級研究課題(ti)等項(xiang)(xiang)目。獲得(de)(de)國(guo)(guo)家(jia)(jia)(jia)(jia)專利12項(xiang)(xiang),國(guo)(guo)內(nei)(nei)外(wai)雜志發表學(xue)(xue)術論文(wen)約249篇,其(qi)(qi)中SCI論文(wen)50余(yu)篇,最(zui)高(gao)IF8.843。主(zhu)編《微創泌尿(niao)外(wai)科(ke)(ke)(ke)(ke)手術學(xue)(xue)》、《前列(lie)腺(xian)癌》等6部(bu)專著,參編《泌尿(niao)外(wai)科(ke)(ke)(ke)(ke)疾病診(zhen)斷(duan)與鑒(jian)別(bie)診(zhen)斷(duan)》等22部(bu)著作,其(qi)(qi)中包(bao)括3部(bu)全國(guo)(guo)衛(wei)生部(bu)統編教(jiao)材。獲得(de)(de)省(sheng)部(bu)級科(ke)(ke)(ke)(ke)學(xue)(xue)技(ji)(ji)(ji)術進(jin)步二等獎(jiang)(jiang)(jiang)(jiang)2項(xiang)(xiang),三等獎(jiang)(jiang)(jiang)(jiang)1項(xiang)(xiang);上(shang)(shang)海市(shi)(shi)(shi)醫(yi)(yi)(yi)學(xue)(xue)科(ke)(ke)(ke)(ke)技(ji)(ji)(ji)進(jin)步二等獎(jiang)(jiang)(jiang)(jiang)1項(xiang)(xiang)、三等獎(jiang)(jiang)(jiang)(jiang)1項(xiang)(xiang);國(guo)(guo)家(jia)(jia)(jia)(jia)教(jiao)育部(bu)科(ke)(ke)(ke)(ke)技(ji)(ji)(ji)進(jin)步二等獎(jiang)(jiang)(jiang)(jiang)1項(xiang)(xiang);中華醫(yi)(yi)(yi)學(xue)(xue)科(ke)(ke)(ke)(ke)技(ji)(ji)(ji)進(jin)步一等獎(jiang)(jiang)(jiang)(jiang)提名及(ji)中華醫(yi)(yi)(yi)學(xue)(xue)科(ke)(ke)(ke)(ke)技(ji)(ji)(ji)進(jin)步二等獎(jiang)(jiang)(jiang)(jiang)1項(xiang)(xiang),獲得(de)(de)上(shang)(shang)海市(shi)(shi)(shi)科(ke)(ke)(ke)(ke)學(xue)(xue)技(ji)(ji)(ji)術進(jin)步獎(jiang)(jiang)(jiang)(jiang)一等獎(jiang)(jiang)(jiang)(jiang)1項(xiang)(xiang)。上(shang)(shang)海市(shi)(shi)(shi)衛(wei)生系統先(xian)(xian)進(jin)個人,上(shang)(shang)海市(shi)(shi)(shi)職工創新十大精英獎(jiang)(jiang)(jiang)(jiang),獲得(de)(de)中國(guo)(guo)內(nei)(nei)鏡(jing)杰出(chu)領袖(xiu)獎(jiang)(jiang)(jiang)(jiang),國(guo)(guo)際內(nei)(nei)鏡(jing)杰出(chu)領袖(xiu)獎(jiang)(jiang)(jiang)(jiang)。2010年國(guo)(guo)家(jia)(jia)(jia)(jia)衛(wei)生部(bu)授予有突出(chu)貢獻的中青年專家(jia)(jia)(jia)(jia)稱號,獲得(de)(de)泌尿(niao)外(wai)科(ke)(ke)(ke)(ke)最(zui)高(gao)榮譽獎(jiang)(jiang)(jiang)(jiang)吳階平醫(yi)(yi)(yi)學(xue)(xue)獎(jiang)(jiang)(jiang)(jiang)。享(xiang)受國(guo)(guo)務院政(zheng)府(fu)特殊津貼。

相關內容推薦
發表評論
您還未登錄,依《網絡安全法》相關要求,請您登錄賬戶后再提交發布信息。點擊登錄>>如您還未注冊,可,感謝您的理解及支持!
最新評(ping)論
暫無評論
網站提醒和聲明
本(ben)站(zhan)為(wei)注冊用(yong)戶(hu)提(ti)(ti)供信(xin)(xin)息(xi)存儲空間服務,非“MAIGOO編輯上傳(chuan)提(ti)(ti)供”的文章/文字均是注冊用(yong)戶(hu)自主發布(bu)上傳(chuan),不代表本(ben)站(zhan)觀點(dian),更不表示本(ben)站(zhan)支持購買和交易,本(ben)站(zhan)對網頁中內(nei)容(rong)的合(he)法性(xing)(xing)、準確(que)性(xing)(xing)、真實性(xing)(xing)、適用(yong)性(xing)(xing)、安全(quan)性(xing)(xing)等(deng)概不負責。版(ban)權歸原作者所有,如(ru)有侵權、虛假信(xin)(xin)息(xi)、錯(cuo)誤(wu)信(xin)(xin)息(xi)或任何(he)問(wen)題(ti),請及時聯系我們(men),我們(men)將在第一時間刪除或更正(zheng)。 申請刪除>> 糾錯>> 投訴侵權>>
提交說明: 查看提交幫助>> 注冊登錄>>
頁面相關分類
熱門模塊
已有3846097個品牌入駐 更新518570個招商信息 已發布1584922個代理需求 已有1343120條品牌點贊